Tag Archives: cardiovascular death

EACVI 2025 Study Finds Severe Valve Disease Raises Mortality Risk in Cancer Patients but Treatment Markedly Improves Outcomes

Posted on 11, December 2025 by EuropaWire PR Editors

(IN BRIEF) A major observational study presented at EACVI 2025 found that valvular heart disease is common in patients with prior cancer diagnoses, with 7.2% showing severe disease on echocardiography. Conditions such as tricuspid and mitral regurgitation and aortic stenosis … Read the full press release →

Posted in Artificial Intelligence (AI), Austria, Business, Education, France, Healthcare, Industrial, Management, Marketing, News, Non Profit, Pharma & Biotech, Science, Technology

Tagged anthracyclines, Aortic Stenosis, cancer survivors, cardio-oncology, cardiotoxicity, cardiovascular death, Cardiovascular Imaging, CESAR study, EACVI 2025, echocardiography, ESC, European Association of Cardiovascular Imaging, European Society of Cardiology, Maximilian Autherith, mitral regurgitation, mortality risk, New Research Highlights Need for Regular Cardiac Monitoring as Cancer Survivors Face High Rates of Valvular Heart Disease, survival benefit, tricuspid regurgitation, valve intervention, valvular heart disease, Vienna

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

Posted on 20, June 2013 by EuropaWire PR Editors

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Science, United Kingdom

Tagged anti-diabetic therapies, AstraZeneca, autoimmune, biopharmaceutical, biopharmaceutical business, Bristol-Myers Squibb, cardiovascular, cardiovascular death, cardiovascular disease, clinical trial, Diabetes Mellitus, Hadassah University Medical Center, infection, inflammation, metabolic, neuroscience diseases, non-fatal ischaemic stroke, non-fatal myocardial infarction, oncology, Onglyza, prescription medicines, respiratory, SAVOR-TIMI-53, saxagliptin, TIMI Study Group, type 2 diabetes